Gara Jalqabaatti › Myelofibrosis › New York › New York City
Qorannoo klinikaalii Myelofibrosis New York City, NY keessatti
Qorannoo 18 Myelofibrosis f New York City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Namoota walitti qabaa jiraSadarkaa 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical Center, New York
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Namoota walitti qabaa jiraSadarkaa 3
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Namoota walitti qabaa jiraSadarkaa 2
- NYP/Weill Cornell Medical Center, New York
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore, New York
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Namoota walitti qabaa jiraSadarkaa 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- Icahn School of Medicine At Mount Sinai, New York
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center, New York
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center, New York
- Mount Sinai School of Medicine, New York
- Weill Cornell Medicine, New York
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Namoota walitti qabaa jiraSadarkaa 2
- Ruttenberg Treatment Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NewYork-Presbyterian/Weill Cornell Medical Center, New York
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Namoota walitti qabaa jiraSadarkaa 2
- GSK Investigational Site, New York
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- Icahn School of Medicine At Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- Memorial Sloan Kettering, New York
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Namoota walitti qabaa jiraSadarkaa 2
- Weill Cornell Medicine NewYork-Presbyterian, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Memorial Sloan Kettering Cancer Center, New York
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Namoota walitti qabaa jiraSadarkaa 2
- Ruttenberg Treatment Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, New York
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Namoota walitti qabaa jiraSadarkaa 3
- ICAHN School of Medicine at Mount Sinai, New York
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Namoota walitti qabaa jiraSadarkaa 1
- Columbia University, New York
Qorannoo Myelofibrosis magaalota biroo keessatti
- Houston, TXQorannoo 19
- Boston, MAQorannoo 12
- Durham, NCQorannoo 12
- Columbus, OHQorannoo 11
- Seattle, WAQorannoo 11
- Salt Lake City, UTQorannoo 10
- Miami, FLQorannoo 10
- Atlanta, GAQorannoo 9
- Baldwin Park, CAQorannoo 9
- Nashville, TNQorannoo 9
- Tampa, FLQorannoo 9
- Cleveland, OHQorannoo 9
Qorannoo biroo New York City keessatti
- Saree OljooQorannoo 136
- Kansara Qara'a Non-Small CellQorannoo 121
- Saree (Gosoota Hunda)Qorannoo 109
- Kansarii ProstateQorannoo 103
- Kansara MetastatikiiQorannoo 93
- Kansarii ColorectalQorannoo 78
- Kansarii OvariiQorannoo 69
- Dhibee QaraQorannoo 60
- Myeloma Baay’eeQorannoo 60
- Kansarii PancreasQorannoo 60
- Kansa EndometiriyaaliiQorannoo 52
- Leukemia Myeloidii HamaaQorannoo 51
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.